| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
- Nuclear factor-κB (NF-κB) ( Incensole is reported as an NF-κB inhibitor) [1]
- Signal transducer and activator of transcription 3 (STAT3): IC50 = 15.8 ± 2.88 μM (inhibition of IL-6-induced STAT3 activation) [1] - Transient receptor potential vanilloid 3 (TRPV3) channel: EC50 = 2.1 ± 0.2 μM (stimulation of TRPV3-mediated calcium influx) [1] |
|---|---|
| ln Vitro |
- In a TRPV3-mediated calcium influx assay, Incensole showed moderate potency with an EC50 value of 2.1 ± 0.2 μM; its efficacy was higher than that of incensole acetate. [1]
- Incensole potently inhibited IL-6-induced STAT3 activation in vitro with an IC50 of 15.8 ± 2.88 μM, whereas incensole acetate was inactive in this assay. [1] - In HeLa cells stimulated with tumor necrosis factor α (TNFα), Incensole (along with incensole acetate) was identified as a nuclear factor-κB (NF-κB) inhibitor via bioassay-guided fractionation, though specific IC50 values for Incensole were not reported. [1] - Incensole (1) was found to be a more potent inhibitor of STAT3 and NF-κB in cellular models compared to incensole acetate, suggesting that in vivo deacetylation of incensole acetate yields the active Incensole form. [1] |
| Enzyme Assay |
- TRPV3-mediated calcium influx assay: Human TRPV3-expressing cells were loaded with a calcium-sensitive fluorescent dye. Incensole was added at various concentrations, and fluorescence changes (indicating intracellular calcium increase) were recorded. The EC50 value (2.1 ± 0.2 μM) was calculated from concentration-response curves. [1]
- STAT3 inhibition assay: Cells were stimulated with interleukin-6 (IL-6) to induce STAT3 activation. Incensole was incubated with the cells, and STAT3 phosphorylation or transcriptional activity was measured. The IC50 for inhibition of IL-6-induced STAT3 activation was determined as 15.8 ± 2.88 μM. [1] |
| Cell Assay |
- HeLa cell NF-κB inhibition assay: HeLa cells were stimulated with TNFα in the presence or absence of Incensole. NF-κB activation was assessed by measuring IκBα degradation or NF-κB-driven reporter gene expression. Incensole was identified as an NF-κB inhibitor through bioassay-guided fractionation of Boswellia resin. [1]
- STAT3 activation assay: Cells were treated with IL-6 to induce STAT3 phosphorylation. Incensole was added at varying concentrations, and the level of STAT3 activation (e.g., by Western blot or reporter assay) was quantified to determine the IC50 of 15.8 ± 2.88 μM. [1] |
| ADME/Pharmacokinetics |
- The reference indicates that incensole acetate is rapidly deacetylated in vivo to yield Incensole, suggesting that Incensole is the active metabolite responsible for the observed in vivo activities. No specific pharmacokinetic parameters (e.g., half-life, bioavailability, protein binding) for Incensole are provided. [1]
|
| References | |
| Additional Infomation |
It has been reported that Boswellia sacra and Sarcophyton glaucum contain (1R,2S,5E,9E,12S)-1,5,9-trimethyl-12-propyl-2-yl-15-oxabicyclo[10.2.1]pentadecano-5,9-dien-2-ol, and there is relevant data.
- Incensole is a cembrane-type diterpene found predominantly in Boswellia papyrifera and Boswellia elongata, while other Boswellia species (e.g., Boswellia sacra, Boswellia carteri, Boswellia serrata) contain only trace amounts or none. [1] - The biosynthetic pathway of Incensole is proposed to start from geranylgeranyl pyrophosphate (GGPP) via 1,14-cyclization to form a 14-membered ring, followed by epoxidation and intramolecular cyclization. Serratol is suggested as a biosynthetic precursor. [1] - Incensole has been used as a precursor for synthetic transformations, including acylation, epoxidation, and oxidation to generate analogs with modified biological activities. [1] - The compound contributes to the anti-inflammatory and antidepressant effects of frankincense, alongside boswellic acids. Its mechanism involves inhibition of NF-κB and STAT3, as well as activation of TRPV3 channels. [1] |
| Molecular Formula |
C20H34O2
|
|---|---|
| Molecular Weight |
306.4828
|
| Exact Mass |
306.256
|
| CAS # |
22419-74-5
|
| PubChem CID |
44583885
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
5.167
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
22
|
| Complexity |
449
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
O1[C@@]2(C([H])([H])[H])[C@]([H])(C([H])([H])C([H])([H])C(C([H])([H])[H])=C([H])C([H])([H])C([H])([H])C(C([H])([H])[H])=C([H])C([H])([H])[C@]1(C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])C2([H])[H])O[H] |t:18,31|
|
| InChi Key |
SSBZLMMXFQMHDP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H34O2/c1-15(2)20-12-11-17(4)8-6-7-16(3)9-10-18(21)19(5,22-20)13-14-20/h7,11,15,18,21H,6,8-10,12-14H2,1-5H3
|
| Chemical Name |
1,5,9-trimethyl-12-propan-2-yl-15-oxabicyclo[10.2.1]pentadeca-5,9-dien-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~815.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2629 mL | 16.3143 mL | 32.6286 mL | |
| 5 mM | 0.6526 mL | 3.2629 mL | 6.5257 mL | |
| 10 mM | 0.3263 mL | 1.6314 mL | 3.2629 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
